Infectious diseases are commonly caused by pathogenic microorganisms such as viruses, bacteria, fungi, and parasites. These diseases are transferred from one individual to the other by direct or indirect contact. Anti-infective drugs prevent the growth of such diseases. These drugs act by a mechanism of the host defense system, which specifically targets the causative agent. Infectious diseases including HIV, malaria, tuberculosis, influenza, hepatitis A and hepatitis C are acute diseases causing notable deaths globally. One of the key factors driving the infectious disease therapeutics market is the growing number of infectious diseases worldwide, which has created a demand for infectious disease therapeutics. Moreover, the favorable reimbursement policies for infectious diseases and the surging consumption of anti-microbial direct-acting drugs are few other factors accountable for the significant growth of the infectious disease therapeutics market in the forecast period. However, the limited number of skilled persons in manufacturing effective drugs is a key factor negatively impacting the market growth. The Infectious Disease Therapeutics Market is anticipated to grow at the rate of 8.9% CAGR by 2027. 

Research Methodology:

The Infectious Disease Therapeutics Market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology and a unique balance of primary insights. The real-time valuation of the market is an integral part of our forecasting and market sizing methodology. Industry experts and our primary participants have helped to compile related aspects with accurate parametric estimations for a complete study. The primary participants share is given below:

Infectious Disease Therapeutics Market on the basis of Mode of Treatment

• Drugs
• Vaccines

Infectious Disease Therapeutics Market on the basis of Disease Indication

• Tuberculosis
• HIV/AIDS
• Influenza
• Hepatitis
• Others

Infectious Disease Therapeutics Market on the basis of Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Infectious Disease Therapeutics Market on the basis of Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on the mode of treatment, the infectious disease therapeutics market is bifurcated into drugs and vaccines. The drug mode of treatment is projected to have a significant share in the market. This is because the increasing population of old around the world is a major attribute to augmenting segment growth. Furthermore, the growing expenditure on healthcare, particularly in the developed countries, is also surging the segment growth.

Based on the disease indication, the infectious disease therapeutics market is segmented by Tuberculosis, HIV/AIDS, Influenza, Hepatitis, and Others. The hepatitis segment is expected to register the highest growth rate in the coming years. The increasing incidence of hepatitis, growing clinical trial activities for the advent of new drugs, and a rising number of initiatives to elevate the adoption of drugs are projected to be the factors responsible for the segment's growth.

Further, the infectious disease therapeutics market is divided into hospital pharmacy, retail pharmacy, and others based on the distribution channel. The hospital pharmacy segment held the maximum share in the market. This is ascribed to the increase in hospital construction with the advanced equipment, and availability of professionals in the hospitals are the key factors.

In the geography market, the geographical regions are categorized into North America, Europe, Asia Pacific, and the rest of the world. Among all the regions, North America has acquired a leading share in the market. Increasing incidence of infectious diseases and favorable reimbursement scenarios are key factors expected to boost infectious disease therapeutics in the region.

The global market for infectious disease therapeutics is significantly driven by the surging number of infectious diseases worldwide, which has surged the demand for therapeutics for infectious diseases. The key reason for the rising number of infectious diseases is the increasing population worldwide, specifically in developing countries including Japan, India, and many other countries.

Top competitors operating in the global infectious disease therapeutics market are Gilead Sciences, Inc., BioCryst Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Janssen Pharmaceutical, Novartis International AG and Astellas Pharma.

Henceforth, the vital burden on public health is presented by various infectious diseases such as HIV, malaria, tuberculosis, hepatitis A, hepatitis C, hepatitis C, and influenza. Therefore, most of the deaths are caused due to infectious diseases where new therapeutics such as drugs and vaccines are having a prominent role in preventing these diseases.

• This study consists of information such as infectious disease therapeutics market dynamics scenarios and opportunities over the forecast period.
• The report provides regional, sub-regional, and country-level analysis, including the demand and supply forces and their influence on the infectious disease therapeutics market.
• The competitive landscape includes the share of key players, new developments, and strategies in the past few years.
• This report also includes the comprehensive companies providing products, relevant financial information, recent developments, SWOT analysis, and strategies by these infectious disease therapeutics market players.

1. Executive Summary
2. Industry Outlook
   1. Industry Overview
   2. Industry Trends
3. Market Snapshot
   1. Market Definition
   2. Market Outlook
      1. Porter Five Forces
   3. Related Markets
4. Market characteristics
   1. Market Overview
   2. Market Segmentation
   3. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
   4. DRO - Impact Analysis
5. Mode of Treatment: Market Size & Analysis
   1. Overview
   2. Drugs
   3. Vaccines
6. Disease Indication: Market Size & Analysis
   1. Overview
   2. Tuberculosis
   3. HIV/AIDS
   4. Influenza
   5. Hepatitis
   6. Others
7. Distribution Channel: Market Size & Analysis
   1. Overview
   2. Hospital Pharmacy
   3. Retail Pharmacy
   4. Others
8. Geography: Market Size & Analysis
   1. Overview
   2. North America
   3. Europe
   4. Asia Pacific
   5. Rest of the World
9. Competitive Landscape
   1. Competitor Comparison Analysis
   2. Market Developments
      1. Mergers and Acquisitions, Legal, Awards, Partnerships
      2. Product Launches and execution
10. Vendor Profiles
    1. Gilead Sciences, Inc.
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    2. BioCryst Pharmaceuticals, Inc.
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    3. F. Hoffmann-La Roche AG
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    4. Merck & Co., Inc.
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    5. Johnson & Johnson
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    6. Boehringer Ingelheim GmbH
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    7. GlaxoSmithKline plc
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    8. Janssen Pharmaceutical
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    9. Novartis International AG
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    10. Astellas Pharma
        1. Overview
        2. Financial Overview
        3. Product Offerings
        4. Developments
        5. Business Strategy
11. Analyst Opinion
12. Annexure
    1. Report Scope
    2. Market Definitions
    3. Research Methodology
       1. Data Collation and In-house Estimation
       2. Market Triangulation
       3. Forecasting
    4. Report Assumptions
    5. Declarations
    6. Stakeholders
    7. Abbreviations